PFIZER INC | 2013 | FY | 3

The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and
Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2013

 
2012

 
2011(c)

 
2013

 
2012

 
2011(c)

 
2013

 
2012

 
2011(c)

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Care(d)
 
$
13,272

 
$
15,558

 
$
22,670

 
$
7,981

 
$
9,613

 
$
15,001

 
$
155

 
$
244

 
$
249

Specialty Care and Oncology
 
14,934

 
15,461

 
16,568

 
10,350

 
10,499

 
10,789

 
351

 
403

 
427

Established Products and Emerging Markets(e)
 
19,672

 
20,195

 
18,509

 
11,159

 
11,217

 
9,417

 
390

 
408

 
430

Total reportable segments
 
47,878

 
51,214

 
57,747

 
29,490

 
31,329

 
35,207

 
896

 
1,055

 
1,106

Consumer Healthcare and other business activities(f)
 
3,574

 
3,443

 
3,288

 
(2,005
)
 
(2,397
)
 
(2,608
)
 
166

 
190

 
223

Reconciling Items:
 
 

 
 

 
 
 
 

 
 

 
 
 
 
 
 
 
 
Corporate
 
—

 
—

 
—

 
(5,800
)
 
(6,112
)
 
(7,317
)
 
382

 
485

 
540

Purchase accounting adjustments(g)
 
—

 
—

 
—

 
(4,344
)
 
(4,905
)
 
(6,672
)
 
4,487

 
4,988

 
5,476

Acquisition-related costs(h)
 
—

 
—

 
—

 
(376
)
 
(946
)
 
(1,913
)
 
124

 
273

 
614

Certain significant items(i)
 
132

 
—

 
—

 
(692
)
 
(5,039
)
 
(4,255
)
 
167

 
300

 
614

Other unallocated(j)
 
—

 
—

 
—

 
(557
)
 
(688
)
 
(961
)
 
84

 
103

 
128

 
 
$
51,584

 
$
54,657

 
$
61,035

 
$
15,716

 
$
11,242

 
$
11,481

 
$
6,306

 
$
7,394

 
$
8,701

(a) 
Income from continuing operations before provision for taxes on income.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
For 2011, includes King commencing on the acquisition date of January 31, 2011.
(d) 
Revenues and Earnings from the Primary Care segment decreased for 2013 as compared to the prior year, and Earnings as a percentage of revenues for 2013 also declined, primarily due to the loss of exclusivity of Lipitor in developed Europe and Australia; the subsequent shift in the reporting of Lipitor in those major markets to the Established Products business unit; the losses of exclusivity of certain other products in various markets; lower Alliance revenues from Spiriva due to the ongoing expiration of the Spiriva collaboration in certain countries; and the termination of the co-promotion agreement for Aricept in Japan in December 2012. Revenues and Earnings from the Primary Care segment decreased for 2012 as compared to 2011, and Earnings as a percentage of revenues also declined, primarily due to the loss of exclusivity of Lipitor in most major markets, and the subsequent shift in the reporting of Lipitor in those major markets to the Established Products business unit.
(e) 
Revenues and Earnings from the Established Products and Emerging Markets segment decreased in 2013 as compared to the prior year, primarily due to the continued erosion of branded Lipitor in the U.S. and Japan, partially offset by the addition of products in certain markets that shifted to the Established Products unit from other business units beginning January 1, 2013 and strong volume growth in China. Revenues and Earnings from the Established Products and Emerging Markets segment increased in 2012 as compared to 2011, primarily due to additional products losing exclusivity and moving to the Established Products unit and increased operational sales in emerging markets, partially offset by unfavorable foreign exchange. Earnings as a percentage of revenue in 2012 increased due to the change in the mix of products.
(f) 
Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the R&D costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
(g) 
Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.
(h) 
Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
(i) 
Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Revenues in 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Divestitures.
For Earnings in 2013, certain significant items includes: (i) patent litigation settlement income of $1.3 billion, (ii) the gain associated with the transfer of certain product rights to our equity-method investment in China of $459 million, (iii) income related to our transitional manufacturing and supply agreements with Zoetis of $16 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (v) certain asset impairments and related charges of $1.1 billion, (vi) other charges of $83 million, (vii) net charges for certain legal matters of $21 million and (viii) costs associated with the separation of Zoetis of $18 million. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Equity-Method Investments, Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.
For Earnings in 2012, certain significant items includes: (i) net charges for certain legal matters of 2.2 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.8 billion, (iii) certain asset impairment charges of $875 million, (iv) costs associated with the separation of Zoetis of $125 million and (v) other charges of $19 million. For additional information see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.
For Earnings in 2011, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $2.5 billion (ii) certain asset impairment charges of $827 million, (iii) charges for certain legal matters of $822 million, (iv) other charges of $69 million and (v) costs associated with the separation of Zoetis of $35 million (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net for additional information).
(j) 
Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment

us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock